Physician profile
William Bartlow
NPI 1881690501
$2,024.14
in general payments reported to CMS, 2019-2025
30 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $97.29 · 2021: $188 · 2022: $172 · 2023: $323 · 2024: $376 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.55 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $230.05 | 2020-2024 | Jardiance, Emgality, Mounjaro |
| Novo Nordisk INC | $169.51 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $155.19 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Tandem Diabetes Care, INC. | $111.51 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.23 | 2020-2022 | |
| Glaxosmithkline, LLC. | $88.91 | 2019-2023 | Bexsero, Rotarix |
| Indivior INC. | $87.02 | 2024-2025 | Sublocade |
| Daiichi Sankyo INC. | $82.21 | 2022-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $75.43 | 2019-2025 | Breztri |
| Kyowa Kirin, INC. | $75.11 | 2024-2025 | Crysvita |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.57 | 2023-2025 | Caplyta |
| Shield Therapeutics INC | $49.36 | 2023-2024 | Accrufer |
| Abbott Laboratories | $48.41 | 2021-2025 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $46.50 | 2019-2024 | Crysvita |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $46.24 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $44.02 | 2019 | |
| Amgen INC. | $39.51 | 2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $30.40 | 2023-2025 | Proquad, Gardasil 9, M-M-R II |
| Phathom Pharmaceuticals, INC. | $29.15 | 2024-2025 | Voquezna |
| Allergan, INC. | $27.65 | 2019 | |
| Alkermes, INC. | $25.17 | 2025 | Vivitrol |
| Pfizer INC. | $22.18 | 2019-2021 | |
| Astellas Pharma US INC | $20.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.35 | 2022 | |
| Therapeuticsmd, INC. | $15.79 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.91 | 2019 | |
| Philips North America LLC | $14.26 | 2022 | |
| Hologic Sales and Service, LLC | $13.60 | 2022 | |
| Shire North American Group INC | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bartlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.